ZYUS LIFE SCIENCES CORP (ZYUS.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:ZYUS - CA9899601095 - Common Stock
ZYUS.CA Key Statistics, Chart & Performance
The current stock price of ZYUS.CA is 0.7 CAD. In the past month the price increased by 2.94%. In the past year, price decreased by -17.65%.
ZYUS.CA Latest News, Press Relases and Analysis
ZYUS.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.81 | 3.59B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.93B | ||
| CRON.CA | CRONOS GROUP INC | 25.43 | 1.36B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.24 | 859.31M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 622.00M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 561.50M | ||
| TSND.CA | TERRASCEND CORP | N/A | 351.25M | ||
| HITI.CA | HIGH TIDE INC | N/A | 362.88M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 357.19M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 21.22 | 343.85M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 302.24M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 278.96M |
Related stock screener links
About ZYUS.CA
Company Profile
ZYUS Life Sciences Corp. is a Canadian-based life sciences company. The company is headquartered in Saskatoon, Saskatchewan. The company went IPO on 2000-10-18. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.
Company Info
ZYUS LIFE SCIENCES CORP
407 Downey Road, Unit 204
Saskatoon SASKATCHEWAN CA
Employees: 0
Phone: 13062422357
ZYUS LIFE SCIENCES CORP / ZYUS.CA FAQ
What does ZYUS do?
ZYUS Life Sciences Corp. is a Canadian-based life sciences company. The company is headquartered in Saskatoon, Saskatchewan. The company went IPO on 2000-10-18. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.
What is the current price of ZYUS stock?
The current stock price of ZYUS.CA is 0.7 CAD.
Does ZYUS LIFE SCIENCES CORP pay dividends?
ZYUS.CA does not pay a dividend.
How is the ChartMill rating for ZYUS LIFE SCIENCES CORP?
ZYUS.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the PE ratio for ZYUS stock?
ZYUS LIFE SCIENCES CORP (ZYUS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.47).
What is ZYUS LIFE SCIENCES CORP worth?
ZYUS LIFE SCIENCES CORP (ZYUS.CA) has a market capitalization of 54.61M CAD. This makes ZYUS.CA a Micro Cap stock.
ZYUS.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ZYUS.CA. When comparing the yearly performance of all stocks, ZYUS.CA is a bad performer in the overall market: 82.74% of all stocks are doing better.
ZYUS.CA Financial Highlights
Over the last trailing twelve months ZYUS.CA reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS increased by 12.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -288.9% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ZYUS.CA Forecast & Estimates
5 analysts have analysed ZYUS.CA and the average price target is 1.53 CAD. This implies a price increase of 118.57% is expected in the next year compared to the current price of 0.7.
For the next year, analysts expect an EPS growth of 18.34% and a revenue growth 16.77% for ZYUS.CA